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Abstract 
Chrysosplenetin is a methoxyflavone with reported anti-cancer effect. We tested its cytotoxic effect 
on the MCF-7 breast cancer cell line, and determined its effect on DNA intercalation and on the 
activity of topoisomerases I and II. The compound inhibited proliferation MCF-7 with an IC50 value 
of 0.29 µM. Chrysosplenetin did not initiate plasmid DNA cleavage but, in a concentration-
dependent manner, protected plasmid DNA against damage induced by Fenton reagents. 
Furthermore, it possessed dual Topoisomerase I and II inhibitory properties. Especially, it inhibited 
topoisomerase II by 83-96% between the range 12.5-100 µM. In the light of these experimental 
findings, molecular docking studies were performed to understand binding mode, interactions and 
affinity of chrysosplenetin with DNA, and with topoisomerases I and II. These studies showed that 
of 4-chromone core and the hydroxyl and methoxy groups important for both intercalation with 
DNA and topoisomerase I and II inhibition. 
 




Chrysosplenetin, (3,6,7,3'-tetra-methylquercetagetin) is a polymethoxylated flavone found in 
some Asteraceae plants like Chamomilla recutita (L.) Rauschert and Artemisia annua L. [1, 2]. 
Reportedly, this compound enhances osteoblastogenesis in human bone marrow stromal cells and 
suppresses postmenopausal osteoporosis in mice [3] It also inhibits the activity of tyrosinase [4] 
and neuraminidase [5] and has antimicrobial properties [6, 7]. Furthermore, it selectively inhibits 
proliferation of breast cancer cell lines MDS-MB-231, MCF-7 and T47D, while having 
comparatively little toxic profiles on normal non-tumour cells (e.g. MRC-5 and HUVEC) [7, 8]. 
Proposed mechanism of action involves triggering PI3K/Akt signaling pathway-associated 
apoptosis, or activating the mitotic spindle checkpoint which alters microtubule depolymerization 
and also results in apoptosis [9]. 
Topoisomerases are enzymes that play a crucial role in DNA replication, recombination, 
transcription and repair [10]. Based on their reaction mechanism, catalytic function, and amino 
acid sequence and consequent tertiary structure, two types of topoisomerase are distinguished in 
humans: topoisomerase I and II [11]. Topoisomerase I acts by cleaving one DNA strand, whereas 
topoisomerase II breaks two strands. Topoisomerase I shows both nuclease and ligase activities. 
The energy released by hydrolysis of the phosphodiester bonds during nuclease activity is stored, 
and used later when the strand is ligated again. Therefore, there is no ATP requirement. In contrast, 
during the ligase activity of the two strands for topoisomerase II, ATP is needed [12]. Many studies 
have shown that certain cancer cells have high level of topoisomerase expression. Thus, 
topoisomerase inhibitors have been widely investigated in the development of new anticancer 
compounds. Daunorubicin, mitoxantrone, teniposide, etoposide, irinotecan and topotecan are used 
as topoisomerases inhibitors for cancer treatment in clinic despite severe adverse effects including 
cardiotoxicity, immune system depression, tremor, and fever [13, 14] Therefore, there is a need for 
novel topoisomerase inhibitors with significantly reduced toxicity profiles. 
Flavonoids are the most common group of polyphenolic compounds in human diet. It is 
widely accepted that the dietary flavonoids in fruits and vegetables play a key role in prevention of 
diseases such as cancer [15, 16]. In addition, some flavonoids exhibit anticancer properties through 
different mechanisms including topoisomerase I and II inhibition [11]. Notably, some of them were 
found to be stronger topoisomerase II inhibitor than etoposide [17]. Taking into account the highly 
promising anticancer properties of chrysosplenetin, we aimed to investigate its interactions with 
DNA, and its inhibitory effects on topoisomerase I and II, through in vitro and in silico studies. 
 
2. Materials and methods 
2.1. Materials and reagents 
Chrysosplenetin, isolated from Artemisia annua L., was a gift from Botanical Developments 
Ltd (Maidstone, UK), >95% purity was confirmed by HPLC-DAD and 1H-NMR. Acetic acid, 
agarose, adenosine 5'-triphosphate disodium salt hydrate (ATP), bovine serum albumin (BSA), 
bromophenol blue, dithiothreitol (DTT), ethylenediaminetetraacatate (EDTA), ethidium bromide 
(EB), glycerol, hydrochloric acid (HCl), hydrogen peroxide (H2O2), iron (II) sulfate (FeSO4) 
magnesium chloride (MgCl2), potassium chloride (KCl), sodium dodecyl sulfate (SDS), 
spermidine, trisma-base (Tris), and xylene cyanol were purchased from Sigma. Supercoiled 
pBR322 plasmid DNA was obtained from Fermantas and topoisomerase I/II enzymes were 
purchased from Topogen. Fetal calf serum (FCS), trypsin–EDTA, Dulbecco's modified Eagle's 
medium (DMEM), penicillin-streptomycin, and L-glutamine were purchased from Biological 
Industries (Kibbutz Beit-Haemek, Israel); dimethyl sulfoxide from Sigma, and MTS Cell 
Proliferation Assay kit from Promega (USA). The DNA cleavage/protective and topoisomerases 
inhibition studies were visualized using BioRad Gel Doc XR system. The results were calculated 
using Image Lab Version 4.0.1 Software program.  
2.2. Cytotoxic effects 
Cytotoxic effects of chrysosplenetin on MCF-7 cell line was evaluated by MTS assay, using 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit (Promega), according the 
manufacturer’s instructions. Briefly, cells suspended in the growth medium were seeded in a 96-
well plate at a density of 10,000 cells per well.  Following a 24-h incubation, chrysosplenetin (0–
10 mM) was added. After incubation for 72 h, 20 ml solution reagent was added to each well and 
the cells were incubated for an additional 1 h. Cell proliferation was determined at 490 nm using a 
UV-VIS spectrophotometer (Bio-Tek Instruments, M-Quant Biomolecular spectrophotometer). 
Cells treated with vehicle alone served as control. The test was repeated three times [18]. 
2.3. Supercoiled pBR322 plasmid DNA hydrolytic cleavage experiments 
The supercoiled pBR322 plasmid DNA (Thermo Scientific, SD0041) hydrolytic cleavage 
activity of chrysosplenetin was examined using agarose gel electrophoresis (Bio-Rad, Wide Mini-
Sub Cell GT Cell). In this work, the stock solution of chrysosplenetin at 10 mM was prepared in 
DMSO and diluted to working solutions (12.5, 25, 50, 100 and 200 µM) with buffer (50 mM Tris-
HCl (pH 7.0)). Control experiments were done in the presence of DMSO (2%). Chrysosplenetin 
was treated with supercoiled pBR322 plasmid DNA at 37 °C for 1 h in the buffer. After incubation, 
loading buffer (bromophenol blue, xylene cyanol, glycerol, EDTA, SDS) was added and the 
reaction mixtures were loaded on agarose gel (0.8%) with EB staining for 90 min at 100 V in TAE 
(Tris-acetic acid-EDTA) buffer. After electrophoresis, band intensities were photographed and 
calculated using BioRad Gel Doc XR system and Image Lab Version 4.0.1 Software program [19].  
2.4. Supercoiled pBR322 plasmid DNA protective experiments 
The supercoiled pBR322 plasmid DNA protective effects of chrysosplenetin against 
oxidative damage of hydroxyl radicals from Fenton reaction were examined using agarose gel 
electrophoresis according to our previously studies [20]. In this work, the reaction mixture 
containing Tris-HCl (pH 7.0), supercoiled pBR322 plasmid DNA, FeSO4 (1 mM), H2O2 (2%), and 
different concentrations of chrysosplenetin (12.5, 25, 50 and 100 µM) were incubated at 37 ºC for 
1 h. The electrophoresis experiments were performed according to the method detailed above.  
2.5. Topoisomerase I and II inhibition assay 
Topoisomerase inhibition assays of chrysosplenetin were performed as described in our 
previously studies with slight modifications [21]. Control experiments were done in the presence 
of DMSO (2%). Briefly, 1 unit of human topoisomerase I (Topogen, TG2005H-RC1) and 
supercoiled pBR322 plasmid DNA was treated with or without chrysosplenetin (12.5, 25, 50 and 
100 µM) in relaxation buffer including Tris-HCl (pH 8.0), BSA, DTT, KCl, MgCl2, and spermidine 
for 1 h at 37 ºC. After incubation, loading buffer (bromophenol blue, xylene cyanol, glycerol, 
EDTA, SDS) was added to the reaction mixture. The reaction mixtures were loaded on agarose gel 
(0.8%) with EB staining for 180 min at 40 V in TAE buffer. After electrophoresis, band intensities 
were photographed and calculated using BioRad Gel Doc XR system and Image Lab Version 4.0.1 
Software program. 
In topoisomerase II inhibition assay, 1 unit of human topoisomerase II (Topogen, TG2000H-
1) and supercoiled pBR322 plasmid DNA was treated with or without chrysosplenetin (12.5, 25, 
50 and 100 µM) in relaxation buffer including Tris-HCl (pH 8.0), ATP, BSA, DTT, KCl, MgCl2, 
and spermidine for 1 h at 37 ºC. The electrophoresis experiments were performed according to the 
method detailed above. 
2.6. Molecular docking studies 
Chrysosplenetin and the co-crystallized ligands were modelled and optimized by 
MacroModel (2019-4: Schrödinger, LLC, New York, NY) using OPLS3e forcefield (2019-4: 
Schrödinger, LLC, New York, NY) and conjugate gradient algorithm [22]. Using AutoDockTools 
(v1.5.7, The Scripps Research Institute, San Diego, CA) [23], the ligands were prepared for 
docking by treating bond orders, hydrogens and adding partial charges (Gasteiger) and converted 
to the pdbqt format. Selected 20 DNA structures (PDB ID: 3AJK [24], 3OIE [25], 3U0U [26], 
3U05 [26], 4AH0 [27], 4IJ0 [28], 4U8B [29], 4U8C [29], 6AST [30], 6GIM [31], 1N37 [32], 1Z3F 
[33], 2DES [34], 2MG8 [35], 3FT6 [36], 4BZT [37], 182D [38], 198D [39], 224D [40], 367D [41]) 
and human topoisomerase I (PDB ID: 1K4T [42]) and II (PDB ID: 3QX3 [43]) in covalent complex 
with DNA were downloaded from the RCSB Protein Data Bank (www.rcsb.org) [44]. The 
macromolecules were prepared using AutoDockTools by removing unwanted residues and chains, 
assigning bond orders, adding hydrogens and Gasteiger charges, and ultimately, saving in pdbqt 
format. Grid maps were generated using AutoGrid (v4.2, Scripps Research Institute, San Diego, 
CA) [23] taking the central coordinates of the co-crystallized ligand for each pdb structure with 60 
grid points for each dimension and 0.375 Å spacing. Chrysosplenetin was docked to each 
macromolecule using the prepared Grid maps and AutoDock (v4.2, Scripps Research Institute, San 
Diego, CA) [23] with the following settings: Lamarckian genetic algorithm was selected, genetic 
algorithm search parameters were set as 2,500,000 for maximum number of evaluations and 150 
as population size, and each ligand was docked 50 times to each macromolecule. The docking score 
(energy of free binding, kcal/mol) of the best pose for each ligand and macromolecule selected 
upon visual evaluation was noted. 
 
3. Results and discussion 
3.1. Cytotoxicity and supercoiled pBR322 plasmid DNA hydrolytic cleavage experiments 
Chrysosplenetin inhibited proliferation of MCF-7 cells with an IC50 value of  0.3 µM after 72 hours 
treatment. Cytotoxicity of chrysosplenetin was evaluated for different treatment times. Sinha et al. 
treated some cancer cell lines MCF-7, HeLa, A549, HEK, T47D as well as a healthy cell line, 
HUVEC for 48 hours and found IC50 values as 4.2, 53.0, 45.0, 48.0, 6.2 and 100 µM, respectively 
[8]. After 24 hours treatment, chrysosplenetin inhibited proliferations of MDA-MB-23 and HT-29 
with IC50 values of 235.0 and 310.0 µM [9]. Our finding is consistent with references. 
In order to evaluate DNA damaging potential of chrysosplenetin, the supercoiled pBR322 
plasmid DNA hydrolytic cleavage products were analyzed using agarose gel electrophoresis. A 
hydrolytic cleavage experiment was performed to evaluate the ability of the compound to damage 
the phosphodiester bonds of supercoiled pBR322 plasmid DNA. In general, pBR322 plasmid DNA 
has three forms in agarose gel electrophoresis. The supercoiled form, which is described as Form 
I, moves fast in the gel. Cleavage of one of the two strands gives the nicked form, described as 
Form II, which moves slower in the gel. If both strands are broken, the linear form of the plasmid, 
Form III, will be generated, which moves in between Form I and II [45]. As seen in Figure 1, 
presence of chrysosplenetin did not result in DNA cleavage at increasing concentrations (12.5, 25, 
50, 100 and 200 µM) since Form I did not change to Form II and III in lane 2-6, i.e. chrysosplenetin 
did not damage the supercoiled pBR322 plasmid DNA under our experimental conditions. 
 
Figure 1. Supercoiled pBR322 plasmid DNA hydrolytic cleavage effect of chrysosplenetin. 
Lane 1, DNA control; lane 2-6, DNA+ chrysosplenetin (12.5 μM-25 μM-50 μM-
100 μM-200 μM). 
 
3.2. Supercoiled pBR322 plasmid DNA protective experiments 
In order to investigate the protective effects of chrysosplenetin against oxidative damage to 
the supercoiled pBR322 plasmid DNA by hydroxyl radicals, we used agarose gel electrophoresis 
and Fenton reaction, which was started by FeSO4 and H2O2 [46]. The results presented in Figure 
2 show that, in absence of chrysosplenetin, Form I disappeared completely, Form II and III were 
observed as 100% due to the DNA damage caused by hydroxyl radicals generated via Fenton 
reaction (Figure 2, lane 2). As shown on lane 3-6 in Figure 2, chrysosplenetin inhibited Fenton-
induced damage of supercoiled pBR322 plasmid DNA in a concentration-dependent manner, 
which was evident by increasing intensities of Form I coinciding with increasing concentrations of 
chrysosplenetin (12.5, 25, 50 and 100 µM). The band intensities of Form I were found as 27.5%, 
28.2%, 73.9% and 78.7%, respectively. In conclusion, chrysosplenetin protects DNA from 
oxidative damage, probably due to its radical scavenging properties [47].  
 
Figure 2. Supercoiled pBR322 plasmid DNA protective effects of chrysosplenetin. Lane 
1: DNA control; lane 2: DNA + 1 mM FeSO4 + 2% H2O2 bant 3-6: DNA + 1 mM 
FeSO4 + 2% H2O2 + chrysosplenetin (12.5 µM-25 µM-50 µM-100 µM). 
 
3.3. Topoisomerase I and II inhibition assay 
The effects of chrysosplenetin on topoisomerase I and II were investigated using agarose gel 
electrophoresis. As shown in Figure 3 and Figure 4 (lane 2), when supercoiled pBR322 plasmid 
DNA was incubated with topoisomerases, Form I changed to Form II and Form III. For 
topoisomerase I, band intensities of Form I increased by 31.0%, 54.1%, 63.5% and 69.0% with 
increasing concentrations of chrysosplenetin (12.5, 25, 50 and 100 µM) and band intensities of 
Form II and III decreased. These results show that chrysosplenetin inhibits topoisomerase I in a 
concentration-dependent manner. In addition, chrysosplenetin showed remarkable inhibitory effect 
against topoisomerase II. The percentages of Form I were determined as 83.5%, 86.4%, 95.6% and 
96.9%, respectively. All of these results demonstrate that chrysosplenetin has dual inhibitory effect 
against topoisomerase I and II. In several previous studies, flavonoids have been shown to inhibit 
topoisomerases. Quercetin and apigenin did not inhibit topoisomerase I-DNA complexes in K562 
cells whereas they were found to moderately inhibit topoisomerase II. Fisetin and myricetin 
reportedly behaved as dual inhibitors of topoisomerase I and II [48]. Some flavonols, quercetin, 
kaempferol, fisetin, and myricetin were reported to inhibit topoisomerase II with IC50 values of 
19.9, 28.0, 28.0, 34.6 µM respectively[49]. Moreover, topoisomerase I bioassay guided isolation 
studies on Paphiopedilum callosum (Rchb.f.) Stein led to isolation of some stilbenoids and two 
flavonoids, galangin and galangin-3-methylether [50]. Topoisomerase I inhibitory effect of 
galangin (range 0.2 -1.2 mM), associated with induction of Topoisomerase I conformation change 
and enhancement of the content of α-helix was also reported in other study [51].  
 
 
Figure 3. Topoisomerase I inhibitory effect of chrysosplenetin. Lane 1: DNA control; lane 
2: DNA + 1 U topoisomerase I; lane 3-6: DNA + 1 U topoisomerase I + 




Figure 4. Topoisomerase II inhibitory effect of chrysosplenetin. Lane 1: DNA control; lane 
2: DNA + 1 U topoisomerase II; lane 3-6: DNA + 1 U topoisomerase II + 
(chrysosplenetin (12.5, 25, 50, 100 μM)). 
 
3.4. Molecular docking studies 
3.4.1. Macromolecule selection and validation of the docking process 
DNA damage through directly targeting DNA molecules is one of the most common 
strategies for designing antiproliferative agents. However, proteins protecting DNA from oxidative 
damage, such as DNA-binding protein Dps, and small molecules helping DNA repair, such as 
flavonoids, are known to bind to DNA [52, 53]. Small molecules can interact with DNA through 
intercalation, i.e. binding in between base pairs, or through groove binding, i.e. interacting with the 
minor and major grooves, which are rich with H bond donor and acceptor groups [54]. Compounds 
with large planar groups such as berberine and daunomycin tend to intercalate in between base 
pairs and polar moieties further stabilize this mode via H-bond interactions with DNA base 
nitrogens. Flexible compounds such as distamycin and netropsin on the other hand, are prone to fit  
Table 1. Structural and co-crystallized ligand information of the selected pdb structures. 
PDB ID Structure 






3AJK DNA groove binding 1.95 0.86 
3OIE DNA groove binding 1.90 0.80 
3UOU DNA groove binding 1.24 0.75 
3U05 DNA groove binding 1.27 0.69 
4AH0 DNA groove binding 1.20 1.22 
4IJ0 DNA groove binding 1.54 0.99 
4U8B DNA groove binding 1.31 0.89 
4U8C DNA groove binding 1.24 0.63 
6AST DNA groove binding NMRb 0.85 
6GIM DNA groove binding 1.43 0.50 
1N37 DNA intercalation NMRb 1.27 
1Z3F DNA intercalation 1.50 2.51 
2DES DNA intercalation 1.50 0.70 
2MG8 DNA intercalation NMRb 1.10 
3FT6 DNA intercalation 1.12 1.89 
4BZT DNA intercalation NMRb 0.77 
182D DNA intercalation 1.80 0.54 
198D DNA intercalation 1.97 0.73 
224D DNA intercalation 1.40 0.64 
367D DNA threading intercalation 1.20 1.76 
1K4T Topo I intercalation 2.10 0.76 
3QX3 Topo II intercalation 2.16 0.51 
a RMSD value of the docked conformer of the co-crystallized ligand regarding its original 
conformer. 
b Structure resolved through solution NMR. 
  
in grooves. Especially minor groove, which has a narrow gorge is quite suitable for flexible small 
molecules rather than large molecules like peptides and proteins [55]. Compounds featuring both 
large planar and flexible groups, such as nogalamycin can both intercalate in between base pairs 
and interact with the grooves, called threading intercalators [56]. Since the binding of a co-
crystallized ligand may affect the results of chrysosplenetin docking, we selected 21 DNA 
structures from the Protein Data Bank, which include co-crystallized ligands with different binding 
types. Those resolved through X-ray crystallography were of 2.0 Å resolution or lower. The co-
crystallized ligand of each DNA molecule was redocked and the RMSD value of the docked ligand 
was calculated regarding the co-crystallized conformation. All the structures, except 1Z3F, yielded 
low RMSD values (Table 1). 1Z3F was discarded and chrysosplenetin was docked to the remaining 
20 DNA molecules. In the case of Topoisomerase I (1K4T) and II (3QX3) the RMSD of the co-
crystallized ligands were excellent (Table 1). 
 
 
3.4.2. Chrysosplenetin’s binding to the DNA structures 
Chrysosplenetin is composed of a 4-chromone ring to which a phenyl ring is attached at the 
2nd position. The compound also has a number of methoxy and hydroxy substituents. Thus, with 
limited flexibility, planarity, and several H-bond donor and acceptor groups, chrysosplenetin was 
expected to display intercalation where possible and minor groove binding where intercalation is 
not possible. According to the results, this expectation was realized; chrysosplenetin showed 
intercalation with the structures having an intercalator co-crystallized ligand. For other structures 
it showed minor groove binding. 2KY7, however was an exception, with which chrysosplenetin 
interacted through groove binding although intercalation was possible (Figure 5 A-C). The 4-
chromone ring intensely engaged in π-π interactions in intercalation mode, while the hydroxyl 
groups made H bonds with the phosphate groups while binding to the groove (Figure 5 D-F) (See 
Supporting Information for more details.). The ability of chrysosplenetin to bind in both ways was 
also evident with the docking scores (Table 2). Docking score of chrysosplenetin was similar in 
most of the structures (within -6.5 and -7.5 kcal/mol range) although binding types were different. 
The scores also demonstrated that chrysosplenetin showed mild affinity to DNA compared to the 
tight binding co-crystallized ligands. 
 
Figure 5. Binding modes (A-C) and interactions (D-F) of chrysosplenetin with 3OIE, 
2DES, and 2KY7, respectively. Chrysosplenetin is represented as sticks and balls and the 
DNA molecules as molecular surface rendered according to the electrostatic potentials of 
the atoms with color ramp red-white-blue, in which red represents the lowest and blue 
represents the highest potential. 
Table 2. Docking scores and binding types of chrysosplenetin with the DNA structures 
 Score (kcal/mol)  




3AJK -7.8 -12.3 groove binding 
3OIE -7.4 -17.3 groove binding 
3U0U -7.6 -12.0 groove binding 
3U05 -7.5 -13.9 groove binding 
4AH0 -7.6 -11.2 groove binding 
4IJ0 -7.9 -14.1 groove binding 
4U8B -7.8 -15.4 groove binding 
4U8C -7.9 -17.5 groove binding 
6AST -6.8 -9.7 groove binding 
6GIM -7.3 -12.5 groove binding 
1N37 -6.1 -7.7 intercalation 
2DES -6.8 -11.9 intercalation 
2MG8 -5.9 -10.9 intercalation 
3FT6 -8.8 -8.0 intercalation 
4BZT -8.4 -14.0 intercalation 
182D -7.1 -11.0 intercalation 
198D -6.6 -10.9 intercalation 
224D -7.0 -9.7 intercalation 
367D -8.2 -9.4 intercalation 





3.4.3. Chrysosplenetin’s binding to the DNA topoisomerases 
The topoisomerase I structure used in this study (1K4T) is a covalent enzyme-DNA transient 
complex state in which the phosphodiester bond is broken at one strand of the DNA and a 3’-
phosphotyrosyl intermediate is formed via Tyr723, instead. The co-crystallized ligand, topotecan, 
binds to the covalent complex by intercalating at the site of DNA cleavage making π-π stacking 
with both base pairs. Topotecan also makes direct and water-mediated H bonds with the enzyme 
Asp533, Asn722, and Tyr723 [42]. The topoisomerase II (3QX3) is also a covalent enzyme-DNA 
transient complex with two identical catalytic sites and in each site either strand of DNA is cut and 
one etoposide is bound. In Topoisomerase II, Tyr821 is engaged in phosphotyrosyl linkage in each 
cleavage site. In this structure, etoposide intercalates in between the base pairs in the cleavage site 
via its polycyclic aglycone core, while, being flexible unlike topotecan, its glycosidic and 4-
hydroxy-3,5-dimethoxyphenyl groups stretch towards DNA major and minor grooves. Amino 
acids Gly478, Asp479, Leu502, Arg503, Gln778 and Met782 of the enzyme, as well as bases C14, 
G13, and T9 are the residues that etoposide interacts with. Topoisomerase poisons, such as 
topotecan and etoposide, tightly bind to and stabilize topoisomerase-DNA transient complexes thus 
prevent reattachment of the broken DNA strands by topoisomerase, which renders the DNA 
nonfunctional [57]. 
Although not as strong as topotecan and etoposide, chrysosplenetin bound to both enzyme-
DNA complexes with fair affinity (Table 3). In topoisomerase I active site, chrysosplenetin was 
observed to intercalate at the DNA cleavage site in a very similar manner as topotecan (Figure 6). 
In this binding mode the 4-chromone and benzene rings made intense π-π interactions with one of 
the base pairs (A113 and T10), while H-bonds were formed with Arg364 and Asn722. The 
compound also bound to topoisomerase II in very similar way with π-π stacks with G13 base 
through the 4-chromone ring and H-bond interactions with Arg503 and Gln778 (Figure 6) (See 
Supporting Information for more details.). 
 
 
Figure 6. Binding modes (A, B) and interactions (C, D) of chrysosplenetin with covalent 
DNA complexes of topoisomerase I and II, respectively. Chrysosplenetin is represented 
as sticks, enzyme backbone as ribbons, and the DNA molecules as molecular surface 
rendered according to the electrostatic potentials of the atoms with color ramp red-white-
blue, in which red represents the lowest and blue represents the highest potential. 
Table 3. Docking scores (kcal/mol) of chrysosplenetin and the co-crystallized ligands with 
topoisomerases 
Structure Chrysosplenetin Co-crystallized ligand 
Topoisomerase 1 -9.1 -12.3 




In this study, we investigated DNA interaction, topoisomerase I and II inhibitory potentials 
of chrysosplenetin. The supercoiled pBR322 plasmid DNA hydrolytic cleavage, protective and 
topoisomerase I and II inhibitory effects were investigated using agarose gel electrophoresis. 
Chrysosplenetin did not show cleavage effects on increasing concentrations, therefore the results 
suggested that chrysosplenetin did not cause to damage of supercoiled pBR322 plasmid DNA. In 
addition, chrysosplenetin inhibited supercoiled pBR322 plasmid DNA damage induced by Fenton 
reactions in a concentration-dependent manner. All of topoisomerase I and II results showed that 
chrysosplenetin behaved as dual inhibitory effect on these enzymes, which may explain the 
cytotoxic effect of chrysosplenetin. 
Molecular docking studies yielded results in line with the in vitro studies. Although not 
very tight, chrysosplenetin was predicted to bind to DNA via either intercalation or minor groove 
binding. This moderate affinity to DNA may be the reason for its protective effect against oxidative 
damage similar to other reported flavonoids. Tight binding to DNA would probably result in DNA 
damage in a similar way observed with DNA-binding antiproliferative agents. Molecular docking 
highlighted the importance of the 4-chromone core and the hydroxyl and methoxy groups for 
interacting with DNA. Similarly, these structures seem to play important roles for binding to both 
DNA-topoisomerase complexes, since the affinity of the compound to these complexes mainly 
results from intercalating in between the base pairs in the cleavage sites. 
In summary, this study highlighted Topoisomerase I and II inhibitory effect, which might 
be another mechanism of anti-cancer activity of chrysosplenetin. 
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Figure S1. Binding interactions chrysosplenetin with 3OIE (A), 2DES (B), 2KY7 (C), 1K4T (D), 
and 3QX3 (E). Chrysosplenetin is represented as sticks and balls, H bond interactions as yellow 
dashes, π-π interactions as blue dashes, DNA molecules as sticks, and topoisomerase (with the 
DNA molecules) as ribbons. 
